Spiral Therapeutics Inc

4 articles about Spiral Therapeutics Inc

• Spiral Therapeutics Announces Collaboration with the Vestibular Disorders Association (VeDA), Advancing Patient-Centric Care in Neurotology

  10/31/2023

  Spiral Therapeutics, Inc. ("Spiral"), a clinical-stage pharmaceutical company leading the way in therapies for inner ear disorders, today announced a strategic partnership with the Vestibular Disorders Association (VeDA).

• Spiral Therapeutics Welcomes New Investment, Cementing Its Leadership in Neurotology

  8/30/2023

  Spiral Therapeutics, Inc., a clinical-stage company focused on delivering therapies for inner ear disorders, announced a new round of financing led by Esperante Ventures and Ferring Ventures SA.

• Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to Board

  3/29/2023

  Spiral Therapeutics, Inc. ("Spiral"), a clinical-stage company focused on delivering therapies for inner ear disorders, announced today the completion of its acquisition of selected assets from Otonomy, Inc.

• Spiral Therapeutics Completes $8.25M Financing and Initiates Phase 2 Trial in Ménière's Disease

  1/9/2023

  Spiral Therapeutics, Inc. ("Spiral"), a clinical-stage company focused on delivering therapies for inner ear disorders, today announced that the Company recently completed an $8.25M financing, with new proceeds that will fund the continuing development of its lead candidate, SPT-2101, for the treatment of inner ear inflammation.